NxStage Appoints New Member to Its Board of Directors and Announces Resignation of Board Member

LAWRENCE, Mass., Oct. 28 /PRNewswire-FirstCall/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the addition of Earl R. Lewis to the Company’s Board of Directors and the resignation of Peter P. Phildius from the Board.

I first want to thank Pete for the contributions he has made to the Company. I have benefited greatly from working closely with him over the last 10 years. We look forward to working with Earl and leveraging his extensive business experience, said Jeff Burbank, Chief Executive Officer of NxStage Medical. His record of successes with high growth technology companies will be of significant value to us as we continue to expand our business.

Mr. Lewis is the current Chairman, President and CEO of Flir Systems Inc. (NYSE: FLIR), a manufacturer of thermal imaging and infrared camera systems. Previously, he served as CEO and President at Thermo Instrument Systems, Inc. He also served Thermo in various executive capacities, including President and Chief Operating Officer, CEO and President of Thermo Optek Corp., and President of Thermo Jarrell Ash Corp. Mr. Lewis is also a member of the board of directors for Harvard Bio Science and American DG Energy.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company’s website at https://www.nxstage.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the contributions Mr. Lewis will make to NxStage’s performance and operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage’s control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements. Certain factors which may affect future operating results are detailed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the period ending June 30, 2008. In addition, the statements in this press release represent NxStage’s expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage’s expectations or beliefs as of any date subsequent to the date of this press release.

Contact:
Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com

SOURCE NxStage Medical, Inc.

Web site: https://www.nxstage.com